Retrospective assessment of HDR brachytherapy dose calculation methods in locally advanced cervical cancer patients: AcurosBV vs. AAPM TG43 formalism
Journal of Applied Clinical Medical Physics · 2025-01 · 26 (1)
DOI: 10.1002/acm2.14549 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Applied Clinical Medical Physics, online erschienen am 09.10.2024. Verfasst von Billie Ann Radcliffe und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Cape Fear Valley Health, Fayetteville, North Carolina, USA. Hauptthemen laut MEDLINE: Brachytherapy, Uterine Cervical Neoplasms, Radiotherapy Planning, Computer-Assisted, Radiotherapy Dosage. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Purpose
This retrospective analysis was completed to investigate the use of a model‐based dose calculation algorithm (MBDCA) AcurosBV, for use in HDR BT treatments for locally advanced cervical cancer treated with tandem and ovoid applicators with interstitial needles.
Methods
A cohort of 32 patients receiving post‐EBRT HDR brachytherapy boost with a prescription dose of 5.5 Gy × 5 fractions to the high‐risk clinical target volume (CTV HR ) were selected for this study. For standard TG43 dose calculation, applicators were manually digitized on the planning images, while for AcurosBV calculations, solid renderings of Titanium Fletcher Suite Delclos (FSD) applicators included in BrachyVision were matched to those used clinically and Ti needles were manually digitized. The dose was recalculated using Varian's AcurosBV 13.5 and dose‐to‐medium‐in‐medium (D m,m ) was reported. EQD2 values for targets and organs at risk were compared between dose calculation formalisms. D 90% and D 98% values were reported for the high and intermediate‐risk CTVs, and values were reported for OARs including bladder, rectum, sigmoid, bowel, and vagina. Due to variability within the patient cohort, the dosimetric impact of AcurosBV was investigated corresponding to planning image modality (CT vs. CBCT), presence of Ti needles, and contrast within vaginal balloons used to stabilize implants. AcurosBV showed lower dosimetric values for all plans compared to TG43.
Results
The average ± standard deviation of dosimetric reduction in D 90% was 4.33 ± 0.09% for CTV HR and 4.12 ± 0.09% for CTV IR . The reduction to OARs was: 4.99 ± 0.15% for bladder, 7.87 ± 0.16% for rectum, 5.79 ± 0.17% for sigmoid, 6.91 ± 0.14% for bowel, and 4.55 ± 0.14% for vagina.
Conclusions
AcurosBV should be utilized for HDR BT GYN cases, treated with tandem and ovoid applicators, with high degrees of heterogeneity and calculated in tandem with TG43.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Cape Fear Valley Health, Fayetteville, North Carolina, USA.
- Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina, USA.
ORCID-Profile: Yongbok Kim
Zitieren
APA
Radcliffe, B. A., Kim, Y., Raffi, J., Ayala-Peacock, D. N., Stephens, S. J., Chino, J., Meltsner, S., & Craciunescu, O. (2025). Retrospective assessment of HDR brachytherapy dose calculation methods in locally advanced cervical cancer patients: AcurosBV vs. AAPM TG43 formalism. Journal of Applied Clinical Medical Physics, 26(1). https://doi.org/10.1002/acm2.14549
Vancouver
Radcliffe BA, Kim Y, Raffi J, Ayala-Peacock DN, Stephens SJ, Chino J, et al. Retrospective assessment of HDR brachytherapy dose calculation methods in locally advanced cervical cancer patients: AcurosBV vs. AAPM TG43 formalism. Journal of Applied Clinical Medical Physics. 2025;26(1). doi:10.1002/acm2.14549
BibTeX
@article{Radcliffe2025,
author = {Radcliffe, Billie Ann and Kim, Yongbok and Raffi, Julie and Ayala-Peacock, Diandra N and Stephens, Sarah J and Chino, Junzo and Meltsner, Sheridan and Craciunescu, Oana},
title = {Retrospective assessment of HDR brachytherapy dose calculation methods in locally advanced cervical cancer patients: AcurosBV vs. AAPM TG43 formalism},
journal = {Journal of Applied Clinical Medical Physics},
year = {2025},
volume = {26},
number = {1},
doi = {10.1002/acm2.14549}
}
EUVIMED